Big Pharma, UK Universities Launch 'Unique' Early Drug Development Fund
This article was originally published in Scrip
AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.
You may also be interested in...
Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.